Invex Therapeutics (ASX:IXC) Cash Receipts from Operating Activities: A$ Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:IXC Invex Therapeutics Ltd ASX:IXC
31 GF Score
Price A$0.12
! 1 Warning Sign
View Full Analysis

What is Invex Therapeutics Cash Receipts from Operating Activities?

Invex Therapeutics ASX:IXC 31 Cash Receipts from Operating Activities is A$ Mil as of Jun. 2026. GuruFocus rates ASX:IXC with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Invex Therapeutics's Cash Receipts from Operating Activities for the six months ended in Jun. 2026 was A$ Mil.

Invex Therapeutics's Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Jun. 2026 was A$ Mil.

Invex Therapeutics Cash Receipts from Operating Activities Related Terms

Invex Therapeutics Cash Receipts from Operating Activities Historical Data

* Premium members only.

The historical data trend for Invex Therapeutics's Cash Receipts from Operating Activities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Invex Therapeutics Cash Receipts from Operating Activities Chart

Invex Therapeutics Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Cash Receipts from Operating Activities
Get a 7-Day Free Trial - - - - -

Invex Therapeutics Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Cash Receipts from Operating Activities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
ASX:IXC
31GF Score
Invex Therapeutics Ltd ASX:IXC
Cash Receipts from Operating Activities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Invex Therapeutics Cash Receipts from Operating Activities Calculation

A company's cash flow from operations for a time period can be determined using either the direct or indirect method. The indirect method modifies the operating section from accrual accounting to a cash basis by taking the net income generated in a period and adding or subtracting changes in the asset and liability accounts to determine the implied cash flow. However, the direct method uses actual cash inflows and outflows from the company's operations directly. Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method.

GuruFocus lists following items in "Cash Receipts from Operating Activities" section for non-financial companies:
Receipts from Customers
Receipts from Government Grants
Other Cash Receipts from Operating Activities

Cash Receipts from Operating Activities for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$ Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Cash Receipts from Operating Activities of A$ Mil mean?
Invex Therapeutics (ASX:IXC) has a Cash Receipts from Operating Activities of A$ Mil as of Jun. 2026. Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method. View historical data for Invex Therapeutics and its competitors.
Is Invex Therapeutics' Cash Receipts from Operating Activities too high?
Invex Therapeutics' current Cash Receipts from Operating Activities is A$ Mil. Overall, Invex Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Invex Therapeutics' Cash Receipts from Operating Activities compare to VRTX and REGN?
Invex Therapeutics' Cash Receipts from Operating Activities of A$ Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Receipts from Operating Activities for a Biotechnology company?
A good Cash Receipts from Operating Activities depends on the Biotechnology industry context. However, Cash Receipts from Operating Activities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Receipts from Operating Activities mean?
A high Cash Receipts from Operating Activities can signal that a stock is expensive relative to its fundamentals. Cash Receipts from Operating Activities represents cash received from operating activitiies in direct method. View historical data for Invex Therapeutics and its competitors. Invex Therapeutics's current Cash Receipts from Operating Activities is A$ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invex Therapeutics stock overvalued right now?
Invex Therapeutics (ASX:IXC) has a current Cash Receipts from Operating Activities of A$ Mil. The current Cash Receipts from Operating Activities is A$ Mil. Invex Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Receipts from Operating Activities calculated?
Cash Receipts from Operating Activities is calculated from a company's financial statements. For Invex Therapeutics (ASX:IXC), the current Cash Receipts from Operating Activities is A$ Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Invex Therapeutics Business Description

Address c/- Automic Group, Level 5, 191 St Georges Terrace, Perth, WA, AUS, 6000
Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.
31GF Score

Get the complete analysis for ASX:IXC

Cash Receipts from Operating Activities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.12
Price